Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

a?? COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing a??
a?? Merck collaboration to discover and develop influenza A/B antiviral
agents progresses a??BOTHELL, WA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.(NASDAQ:A COCP), (a??Cocrystala?? or the a??Companya??),A a clinical stage biotechnologyA company discoveringA and developingA novel antiviral therapeutics, today announced its financial results for the quarter ended June 30, 2020 and provided program updates.Recent Highlights

Expanded license with Kansas State University Research Foundation (a??KSURFa??) for rights to additional broad-spectrum antiviral compounds to treat Coronavirus infections.

Publication by collaborators of data demonstrating potent in vitro inhibition against Coronavirus in Science Translational Medicine Journal.

Appointed Roger D. Kornberg, Ph.D., a Nobel Laureate to its Board of Directors.

a??We have continued to move our antiviral programs forward. We are encouraged by our preclinical studies of COVID-19 inhibitors,a?? commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. a??With a foundation of strong fundamentals, we believe Cocrystal is poised to build shareholder value.a??
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »